Breast Cancer-specific Survival
Conditions
Brief summary
A population-based case-cohort study of breast cancer-specific survival among all first invasive breast cancer cases
Interventions
DRUGneoadjuvant/adjuvant therapy
chemotherapy/endocrine therapy/surgery/radiotherapy
Sponsors
Center for New Medical Technologies, Novosibirsk, Russia
I.M. Sechenov First Moscow State Medical University
Center of Personalized Medicine, Pirogova
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
All women with stage I-III disease who survived at least 12 months post-diagnosis
Exclusion criteria
Unknown cause of death Treatment outside the region (thus precluding the treatment assessment)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of guideline-consistent and personalized EBM recommendations | 3-year | The percentage of guideline-consistent and personalized EBM recommendations acted on by clinicians in patients with first invasive breast cancer. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-consistent therapy and personalized EBM therapy will be adjudicated by core laboratory. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Breast cancer-specific survival | 3-year | All deaths due to breast cancer-related causes |
| Quantify the performance of the CDSS (MedicBK) algorithm | 3-year | Quantify the performance of the CDSS (MedicBK) algorithm for presents treatment suggestions in frame of guideline-based therapy and personalized EBM therapy: the sensitivity, specificity, NPV, and PPV |
| Predictors | 3-year | Predictors of guideline-consistent and personalized EBM adherence |
Countries
Russia
Contacts
Primary ContactEvgeny Pokushalov, Prof. MD PhD
Backup ContactIrina Ostanina, MD
Outcome results
None listed